Abstract Empirical research supports the use of psychoactive drugs to augment psychotherapy for the treatment of mental illness. The use of such drugs, however, is still resisted by many in the medical community and this transfers to resistance in the wider community. The stigma of controversy surrounding the drugs, further enhanced by the stigma of mental illness, hinders community acceptance....
ABSTRACT Introduction Pharmacotherapy of depression is characterized by the delayed onset of action, chronic treatment requirements, and insufficient effectiveness. Ketamine, with its rapid action and long-lasting effects, represents a breakthrough in the modern pharmacotherapy of depression. Areas covered The current review summarizes the latest findings on the mechanism of the antidepressant...
Abstract Objective: Psychedelic-assisted therapies are emerging as safe and effective treatments for some psychological conditions including depression, anxiety, posttraumatic stress disorder, and substance use disorders. As ketamine therapy is already available in general medicine and 3,4 Methylenedioxymethamphetamine (MDMA) and psilocybin are in late-stage clinical trials, neuropsychologists...
ABSTRACT In the past decade, the consumption of psilocybin mushrooms has become a popular therapeutic tool for people looking to deal with mental and emotional health issues. The emerging interest in psilocybin therapy in the global north has led to the development of retreat centers in locations where psilocybin is legal or unregulated. Drawing on ethnographic research at a psilocybin retreat...
There is mounting evidence suggesting psychedelic and entactogen medicines (namely psilocybin and 3,4-methylenedioxymethamphetamine [MDMA]), in conjunction with proper psychosocial support, hold the potential to provide safe, rapid acting, and robust clinical improvements with durable effects. In the US, both psilocybin and MDMA have been granted Breakthrough Therapy designations by the US Food...
Abstract Background and aims There is growing evidence that psilocybin, a serotonergic psychedelic substance, may be useful in the treatment of substance use disorders. However, there is a lack of data on the beliefs and attitudes towards psilocybin amongst Black individuals diagnosed with Opioid Use Disorder (OUD). This study characterized psilocybin use patterns and perception of risk amongst...
A sharp increase in the prevalence of neuropsychiatric disorders, including major depression, anxiety, substance use disorders and posttraumatic stress disorder (PTSD) has occurred due to the traumatic nature of the persisting COVID-19 global pandemic. PTSD is estimated to occur in up to 25% of individuals following exposure to acute or chronic trauma, and the pandemic has inflicted both forms...
The heralded psychedelic renaissance is currently at a new level where psychedelics are being accepted by the scientific community and the public. Medicalization and the ongoing introduction of market forces are imposing a trend in which psychedelic treatments are reduced to focus into strictly pharmacological and psychological effects on the self, rather than interactions with broader social...
An emerging body of research suggests that psychedelic experiences can change users' religious or metaphysical beliefs. Here I explore issues concerning psychedelic-induced belief change via a critique of some recent arguments by Wayne Glausser. Two scientific studies seem to show that psychedelic experiences can convert atheists to belief in God, but Glausser holds that academic and popular...
Метою дослідження є характеристика методу РАТ (Psychedeilc Assisted Therapy) та окреслення перспектив його впровадження в Україні. Методологія та методи. Використано методи теоретичного аналізування наукової літератури. Результати. З’ясовано, що за попередніми оцінками, щонайменше 23.5 млн. українських громадян ризикують зустрітися з погіршенням психічного здоров’я: до 20.0% з них – середнього...